Rogers James L, De La Cruz Minyety Julianie, Vera Elizabeth, Acquaye Alvina A, Payén Samuel S, Weinberg Jeffrey S, Armstrong Terri S, Weathers Shiao-Pei S
Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Center for Nursing Research, Cizik School of Nursing, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Neurooncol Pract. 2022 Feb 17;9(3):219-228. doi: 10.1093/nop/npac013. eCollection 2022 May.
Patients with primary brain tumors (PBT) face significant mobility issues related to their disease and/or treatment. Here, the authors describe the preliminary utility and feasibility of two established mobility measures, the Timed-Up-and-Go (TUG) and Five-Times Sit-to-Stand (TSS) tests, in quickly and objectively assessing the mobility status of PBT patients at a single institution's neuro-oncology clinic.
Adult patients undergoing routine PBT care completed the TUG/TSS tests and MD Anderson Symptom Inventory-Brain Tumor module (MDASI-BT), which assessed symptom burden and interference with daily life, during clinic visits over a 6-month period. Research staff assessed feasibility metrics, including test completion times/rates, and collected demographic, clinical, and treatment data. Mann-Whitney tests, Kruskal-Wallis tests, and Spearman's rho correlations were used to interrogate relationships between TUG/TSS test completion times and patient characteristics.
The study cohort included 66 PBT patients, 59% male, with a median age of 47 years (range: 20-77). TUG/TSS tests were completed by 62 (94%) patients. Older patients ( < .001) and those who were newly diagnosed ( = .024), on corticosteroids ( = .025), or had poor (≤80) KPS ( < .01) took longer to complete the TUG/TSS tests. Worse activity-related (work, activity, and walking) interference was associated with longer TUG/TSS test completion times ( < .001).
The TUG/TSS tests are feasible for use among PBT patients and may aid in clinical care. Older age, being newly diagnosed, using corticosteroids, poor (≤80) KPS, and high activity-related interference were associated with significant mobility impairment, highlighting the tests' potential clinical utility. Future investigations are warranted to longitudinally explore feasibility and utility in other practice and disease settings.
原发性脑肿瘤（PBT）患者面临与疾病和/或治疗相关的显著行动能力问题。在此，作者描述了两种既定的行动能力测量方法，即定时起立行走（TUG）测试和五次坐立试验（TSS），在一家机构的神经肿瘤门诊快速、客观地评估PBT患者行动能力状况方面的初步效用和可行性。
在6个月的门诊期间，接受常规PBT护理的成年患者完成了TUG/TSS测试以及MD安德森症状问卷-脑肿瘤模块（MDASI-BT），后者评估症状负担以及对日常生活的干扰。研究人员评估了可行性指标，包括测试完成时间/率，并收集了人口统计学、临床和治疗数据。采用曼-惠特尼检验、克鲁斯卡尔-沃利斯检验和斯皮尔曼等级相关分析来探究TUG/TSS测试完成时间与患者特征之间的关系。
研究队列包括66例PBT患者，男性占59%，中位年龄47岁（范围：20 - 77岁）。62例（94%）患者完成了TUG/TSS测试。年龄较大的患者（P <.001）、新诊断的患者（P =.024）、使用皮质类固醇的患者（P =.025）或 Karnofsky 功能状态评分（KPS）较差（≤80）的患者（P <.01）完成TUG/TSS测试所需时间更长。与活动相关（工作、活动和行走）的干扰越严重，TUG/TSS测试完成时间越长（P <.001）。
TUG/TSS测试在PBT患者中使用是可行的，可能有助于临床护理。年龄较大、新诊断、使用皮质类固醇、KPS较差（≤80）以及与活动相关的干扰程度高与显著的行动能力损害相关，凸显了这些测试潜在的临床效用。未来有必要进行进一步研究，纵向探索在其他临床实践和疾病背景下的可行性和效用。
